US5110987A - Method of preparing sphingosine derivatives - Google Patents
Method of preparing sphingosine derivatives Download PDFInfo
- Publication number
- US5110987A US5110987A US07/208,390 US20839088A US5110987A US 5110987 A US5110987 A US 5110987A US 20839088 A US20839088 A US 20839088A US 5110987 A US5110987 A US 5110987A
- Authority
- US
- United States
- Prior art keywords
- group
- hydrogen
- consisting essentially
- derivative
- sphingosine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
- C07C215/24—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and acyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D263/06—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms
Definitions
- the present invention relates to a method of preparing sphingosine derivatives, including, but not limited to, the four enantiomers of sphingosine.
- Sphingolipids i.e., ceramides, sphingomyclin and gangliosides
- Sphingolipids constitute a broad class of biologically important compounds. These materials are known to act as biological response modifiers, and have potential uses in the treatment of diseases in which the progression of the disease, or in which the therapy for the disease, involves growth factors, hormones, or a variety of drugs based on the mechanism of action of such compounds.
- sphingosine is a potent inhibitor of protein kinase C in vivo and in vitro.
- the present invention relates to a method of preparing sphingosine derivatives. It also relates to the stereoselective synthesis of enantiomerically pure dihydroxyalkene primary amines and related compounds, including each of the four enantiomers of sphingosine from either L- or D- serine. Included in the method is the diastereoselective addition of acetylide anions to the following aldehyde to form propargyl alcohol with high erythro selectivity: ##STR1##
- the erythro-isomer of propargyl alcohol is inverted by S N 2 inversion to form a threo-isomer.
- Either isomer can then be deprotected to form an alkyne with a 2-aminopropane 1,3-diol head group; this alkyne can be reduced to form sphingosine or a sphingosine derivative which can be functionalized at the 4 and 5 positions to form a substituted derivative of sphingosine.
- the aldehyde itself is prepared by reducing serine methyl ester by a hydride reagent, and particularly an aluminum hydride reagent such as is used in DIBAL reduction.
- FIG. 1 illustrates the synthesis of sphingosine derivatives according to the present invention
- FIG. 2 illustrates a ⁇ -chelation controlled model according to the present invention
- FIG. 3 illustrates a potential compound capable of being prepared according to the present invention.
- the backbone component of sphingolipids is the long chain base sphingosine, which is typically present as its D(+)-erythro isomer (2S, 3R), that is: ##STR2##
- FIG. 1 The process of the present invention is set forth in FIG. 1.
- DIBAL reduction of the serine methyl ester 3 in toluene at -78° C. provides an approximately 85% yield of an aldehyde 4.
- the reduction may be carried out by using a hydride reagent which stops the reaction at the aldehyde oxidation state.
- aluminum hydride reagents including lithium aluminum hydride, have been found effective.
- the resulting aldehyde has a 2-aminopropane 1, 3 diol head group.
- This aldehyde 4 has been found to be an extremely useful intermediate for the preparation of sphingosine derivatives, and particularly each of the enantiomers of sphingosine.
- erythro sphingosine 9 on a small scale (i.e. approximately 10-100 mg), dehydrosphingosine 8 was exposed to a refluxing solution of excess lithium in liquid ammonia/THF (1, 2, 3, 4-Tetrahydro-9-fluorenone) (4:1) for approximately 7 hours. This resulted in a quantitative recovery of a 9:1 mixture of the erythro sphingosine 9 and dehydrosphingosine 8, respectively. Pure erythro sphingosine 9 is obtained by recrystallization of the mixture from hexane.
- the erythro-selectivity in the conversion of the aldehyde 4 to propargyl alcohol 5 is shown in the ⁇ -chelation-controlled model set forth in FIG. 2.
- This ⁇ -chelation may be used as a means of inverting the stereochemistry of the C-3 alcohol to obtain the corresponding threo-isomer by converting propargyl alcohol to its corresponding ketone 10, shown in FIG. 3, by Swern oxidation to provide an 80% yield, followed by subsequent reduction.
- Erythro alcohol 5 has been found to be cleanly isomerized to its corresponding threo-isomer 6 in 70% yield by Mitsunobu inversion of the C-3 alcohol.
- the threo-isomer 6 can then be converted to threo-sphingosine in yields which are consistently within 2% of those obtained in the erythro series.
- reaction was quenched with saturated NH 4 Cl at 0°, brought to room temperature, THF was evaporated, diluted with Et 2 O, and the aqueous layer was separated and discarded. The organic layer was washed with water, brine and dried over MgSO 4 , and the ether was evaporated in vacuo.
- alkynol 3 (5 gms, 12.6 mmol) of alkynol 3 was dissolved in 100 mls EtOAc and cooled to 0° C. 100 mls of 4N EtOAc was added at 0° C. and the reaction stirred for 4 hrs. The reaction was quenched with 10% NH 4 OH and basified to pH>10. The aqueous layer was separated and extracted 3 times with 50 mls EtOAc. The organic layers were combined and washed with water and brine, dried over MgSO 4 and EtOAc was evaporated in vacuo.
- Alkynol 2 (3 gms, 6.87 mmol) and (Ph) 3 P(1.1 eq, 7.55 mmol, 1.98 gms) were dissolved in 40 mls dry benzene and stirred for 30 mins under N 2 atmosphere.
- Benzoic acid (1.1 eq, 7.55 mol, 0.92 gms) in 20 mls benzene was then added followed by DEAD (1.2 eq, 8.23 mmol, 1.43 gms, 1.30 mls) also in 20 mls of benzene.
- the present invention provides a synthesis which allows the preparation of sphingosine derivatives, and particularly each of the four enantiomers of sphingosine on a multigram scale. Furthermore, the sequence permits easy modification of head group functionality, i.e., substitution at nitrogen or oxygen, and hydrophobicity by the addition of alkyne of different chain lengths to the aldehyde 4. This is shown in FIG. 3, wherein the modification may include the substitution of either hydrogen, hydroxyl, alkoxy, amino, alkylamino or dialkylamino at sites W, X, Y and/or Z. Also, hydrogen, alkyl or aryl may be added to sites R 1 , R 2 and/or R 3 . The process particularly allows the synthesis in an enantiomerically pure state of all possible configurations at C-2, C-3, C-4 and C-5.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
A method of preparing a substituted derivative of sphingosine comprising the steps of reducing serine methyl ester by a hydride reagent to form an aldehyde or aldehyde derivative, adding acetylide anions to the aldehyde to form an erythro-isomer or propargyl alcohol and inverting the propargyl alcohol by SN 2 inversion to form a threo-isomer. Either isomer can then be deprotected to form an alkyne with a 2-aminopropane 1,3-diol head group; this alkyne can be reduced to form sphingosine or a sphingosine derivitive which can be functionalized at the 4 and 5 positions to form a substituted derivative of sphingosine.
Description
The U.S. Government has rights in this invention pursuant to Grant Nos. GM33369 and GM26908, Winship Cancer Center Grant from the National Institute of Health.
The present invention relates to a method of preparing sphingosine derivatives, including, but not limited to, the four enantiomers of sphingosine.
Sphingolipids (i.e., ceramides, sphingomyclin and gangliosides) constitute a broad class of biologically important compounds. These materials are known to act as biological response modifiers, and have potential uses in the treatment of diseases in which the progression of the disease, or in which the therapy for the disease, involves growth factors, hormones, or a variety of drugs based on the mechanism of action of such compounds. For example, it is known that sphingosine is a potent inhibitor of protein kinase C in vivo and in vitro.
There exists a need, therefore, for a method of efficiently preparing sphingosine derivatives.
There also exists a need for a synthetic route to each of the sphingosine enantiomers which not only permits the stereoselective production and biological assay of these materials, but which also provides the flexibility to do extensive structure and function modifications.
The present invention relates to a method of preparing sphingosine derivatives. It also relates to the stereoselective synthesis of enantiomerically pure dihydroxyalkene primary amines and related compounds, including each of the four enantiomers of sphingosine from either L- or D- serine. Included in the method is the diastereoselective addition of acetylide anions to the following aldehyde to form propargyl alcohol with high erythro selectivity: ##STR1##
The erythro-isomer of propargyl alcohol is inverted by S N 2 inversion to form a threo-isomer. Either isomer can then be deprotected to form an alkyne with a 2-aminopropane 1,3-diol head group; this alkyne can be reduced to form sphingosine or a sphingosine derivative which can be functionalized at the 4 and 5 positions to form a substituted derivative of sphingosine. The aldehyde itself is prepared by reducing serine methyl ester by a hydride reagent, and particularly an aluminum hydride reagent such as is used in DIBAL reduction.
FIG. 1 illustrates the synthesis of sphingosine derivatives according to the present invention;
FIG. 2 illustrates a β-chelation controlled model according to the present invention; and
FIG. 3 illustrates a potential compound capable of being prepared according to the present invention.
The backbone component of sphingolipids is the long chain base sphingosine, which is typically present as its D(+)-erythro isomer (2S, 3R), that is: ##STR2##
The process of the present invention is set forth in FIG. 1. Starting from either N-BOC-D- or L-serine (BOC=t-butyloxycarbonyl), one can produce a protected serine methyl ester 3 in approximately 62% overall yield by a series of standard synthetic manipulations, such as those set forth in FIG. 1. DIBAL reduction of the serine methyl ester 3 in toluene at -78° C. provides an approximately 85% yield of an aldehyde 4. The reduction may be carried out by using a hydride reagent which stops the reaction at the aldehyde oxidation state. For example, aluminum hydride reagents, including lithium aluminum hydride, have been found effective. The resulting aldehyde has a 2- aminopropane 1, 3 diol head group. This aldehyde 4 has been found to be an extremely useful intermediate for the preparation of sphingosine derivatives, and particularly each of the enantiomers of sphingosine.
It has been found that the addition of acetylide anions, and particularly alkali acetylides such as the lithium salt of pentadecyne in THF (-78° C. to 0° C.), to the aldehyde 4 produces propargyl alcohol 5 as an approximately 9:1 mixture of erythro- and threo-isomers, respectively, in approximately 90% isolated yield. The erythro- and threo-isomers may be readily separated by chromatography on silica gel (i.e. hexane/ethyl acetate, 2:1). Conversion of the propargyl alcohol 5 to dehydrosphingosine 8 may be achieved using any standard deprotection sequence, such as shown in FIG. 1.
To obtain erythro sphingosine 9 on a small scale (i.e. approximately 10-100 mg), dehydrosphingosine 8 was exposed to a refluxing solution of excess lithium in liquid ammonia/THF (1, 2, 3, 4-Tetrahydro-9-fluorenone) (4:1) for approximately 7 hours. This resulted in a quantitative recovery of a 9:1 mixture of the erythro sphingosine 9 and dehydrosphingosine 8, respectively. Pure erythro sphingosine 9 is obtained by recrystallization of the mixture from hexane.
To overcome problems associated with maintaining relatively constant amounts of ammonia during large scale dissolving metal reductions, the lithium aluminum hydride reduction is altered by switching solvents from refluxing THF (BP=67° C.) to refluxing DME (dimethoxyethane, BP=85° C.) for 12 hours. This results in consistent yields of 70% on scales up to 5 grams.
The erythro-selectivity in the conversion of the aldehyde 4 to propargyl alcohol 5 is shown in the β-chelation-controlled model set forth in FIG. 2. This β-chelation may be used as a means of inverting the stereochemistry of the C-3 alcohol to obtain the corresponding threo-isomer by converting propargyl alcohol to its corresponding ketone 10, shown in FIG. 3, by Swern oxidation to provide an 80% yield, followed by subsequent reduction. Erythro alcohol 5 has been found to be cleanly isomerized to its corresponding threo-isomer 6 in 70% yield by Mitsunobu inversion of the C-3 alcohol. The threo-isomer 6 can then be converted to threo-sphingosine in yields which are consistently within 2% of those obtained in the erythro series.
Illustrative examples of the synthesis of sphingosine derivatives according to the present invention are as follows:
(1.3 eq, 56.7 mmol, 11.8 gms, 14.9 mls) 1-pentadecyne was dissolved in 400 mls by THF and cooled to -78° C. and stirred under N2 atmosphere. (1.3 eq, 3.6 gms) n-BuLi was then added in 1 ml increments and after the last addition, reaction mixture was stirred for 30 min. (10 gms, 1 eq) of the aldehyde was dissolved in 60 mls THF and added dropwise over a 1 hr period. After the aldehyde was added, the reaction mixture was stirred for an additional 30 mins at -78° C., then brought to 0° for 2 hrs. The reaction was quenched with saturated NH4 Cl at 0°, brought to room temperature, THF was evaporated, diluted with Et2 O, and the aqueous layer was separated and discarded. The organic layer was washed with water, brine and dried over MgSO4, and the ether was evaporated in vacuo.
______________________________________
Percent yield: 86%
Purification: Flash column
RF = 0.5 1:7 EtOAc/Hexanes
(EtOAc/Hexanes 1:2)
Erythro/Threo: 9:1
______________________________________
(5 gms, 11.4 mmol) of alkynol 2 was dissolved in 250 mls MeOH and 100 mls water and the reaction mixture was stirred (upon addition of water, the reaction mixture becomes milky white). 400 mgs TsOH is added and the reaction is refluxed for 4 hrs. Evaporate in vacuo MeOH. 400 mls EtOAc was added and mixture was basified with saturated NaHCO3, the layers were separated and organic layer washing with water and brine, and dried over MgSO4. EtOAc was evaporated in vacuo.
______________________________________ Percent Yield: 86% Product recrystallized RF = 0.18 from Et.sub.2 O/Hexane (EtOA c/Hexane 1:2) ______________________________________
(5 gms, 12.6 mmol) of alkynol 3 was dissolved in 100 mls EtOAc and cooled to 0° C. 100 mls of 4N EtOAc was added at 0° C. and the reaction stirred for 4 hrs. The reaction was quenched with 10% NH4 OH and basified to pH>10. The aqueous layer was separated and extracted 3 times with 50 mls EtOAc. The organic layers were combined and washed with water and brine, dried over MgSO4 and EtOAc was evaporated in vacuo.
______________________________________
Percent yield: 90% Purification recrystallized
from Et.sub.2 O/hexanes
______________________________________
(1 gm, 3.37 mmol) of alkynol 4 was dissolved in 30 mls DME (1,2-dimethoxyethane). 1.5 gms LAH was added as the reaction was refluxed under N2 atmosphere for 24 hrs. The reaction was quenched with dilute NaOH and then diluted with Et2 O and hexanes. The salts were stirred for 30 min and the mixture was filtered. The filtrate was washed with Et2 O. The organics were dried over MgSO4 and the solvents were evaporated in vacuo.
______________________________________
Percent yield: 95%
Purification: recrystallization
in CHCl.sub.3 /hexanes
______________________________________
Alkynol 2 (3 gms, 6.87 mmol) and (Ph)3 P(1.1 eq, 7.55 mmol, 1.98 gms) were dissolved in 40 mls dry benzene and stirred for 30 mins under N2 atmosphere. Benzoic acid (1.1 eq, 7.55 mol, 0.92 gms) in 20 mls benzene was then added followed by DEAD (1.2 eq, 8.23 mmol, 1.43 gms, 1.30 mls) also in 20 mls of benzene. The reaction was stirred for 24 hours, the benzene was evaporated in vacuo, diluted with Et2 O, and the organic layer was extracted with NaHCO3, water, and brine. The organics were dried with MgSO4 and evaporated in vacuo.
______________________________________
Percent yield: 69%
Purification: Flash column
RF = 0.78 EtOAc:Hexanes (1:10)
(EtOAc:hexanes 1:2)
______________________________________
(1 gm, 1.85 mmol) of compound 6 was dissolved in 50 mls THF and 50 mls of 10% KOH was then added. The reaction was refluxed for 24 hrs, the THF evaporated in vacuo, diluted with Et2 O, and the layers were separated. The organic layer was extracted with H2 O and brine, dried over MgSO4 and evaporated in vacuo.
______________________________________
Percent yield: 90%
Purification: Flash column
RF = 0.5 ETOAc:Hexanes (1:5)
______________________________________
The present invention provides a synthesis which allows the preparation of sphingosine derivatives, and particularly each of the four enantiomers of sphingosine on a multigram scale. Furthermore, the sequence permits easy modification of head group functionality, i.e., substitution at nitrogen or oxygen, and hydrophobicity by the addition of alkyne of different chain lengths to the aldehyde 4. This is shown in FIG. 3, wherein the modification may include the substitution of either hydrogen, hydroxyl, alkoxy, amino, alkylamino or dialkylamino at sites W, X, Y and/or Z. Also, hydrogen, alkyl or aryl may be added to sites R1, R2 and/or R3. The process particularly allows the synthesis in an enantiomerically pure state of all possible configurations at C-2, C-3, C-4 and C-5.
Claims (46)
1. A method of preparing a threo-isomer of a derivative of sphingosine, wherein said derivative of sphingosine comprises the formula: ##STR9## wherein X and Y are selected from the group consisting essentially of hydrogen, hydroxyl, alkoxy, amino, alkylamino and dialkylamino and wherein R1 is selected from the group consisting essentially of hydrogen, alkyl and aryl, comprising the steps of:
a) adding acetylide anions to an aldehyde or a derivative of said aldehyde that is capable of forming said derivative of sphingosine in substantially the same manner as said aldehyde to form an erythro-isomer of propargyl alcohol, said aldehyde having the formula: ##STR10## b) inverting said propargyl alcohol by SN 2 inversion to form a threo-isomer of propargyl alcohol;
c) acidifying said threo-isomer to form a diol having the formula: ##STR11## wherein R is selected from the group consisting essentially of hydrogen, alkyl and aryl;
d) cleaving said diol to form an amine having the formula: ##STR12## e) reducing said amine to form an alkene having the formula: ##STR13## and f) adding a functional group selected from the group consisting of hydrogen, hydroxyl, alkoxy, amino, alkylamino, and dialkylamino to the 4 and 5 position of said alkene to form said threo-isomer of a derivative of sphingosine.
2. The method of claim 1, wherein said acetylide anions comprise alkali acetylides.
3. The method of claim 1, wherein said acetylide anions comprise 1-lithiopentadecyne.
4. The method of claim 1, wherein said SN 2 inversion is a Mitsunobu inversion.
5. The method of claim 1, wherein said substituted derivative of sphingosine has a 2-aminopropane 1,3 diol head group.
6. The method of claim 1, further comprising the step of adding a functional group to said derivative of sphingosine to form a compound of the formula: ##STR14## wherein W is selected from the group consisting essentially of hydrogen, hydroxyl, alkoxy, amino, alkylamino and dialkyamino;
wherein X is selected from the group consisting essentially of hydrogen, hydroxyl, alkoxy, amino, alkylamino and dialkyamino;
wherein Y is selected from the group consisting essentially of hydrogen, hydroxyl, alkoxy, amino, alkylamino and dialkyamino;
wherein Z is selected from the group consisting essentially of hydrogen, hydroxyl, alkoxy, amino, alkylamino and dialkyamino;
wherein R1 is selected from the group consisting essentially of hydrogen, alkyl and aryl;
wherein R2 is selected from the group consisting essentially of hydrogen, alkyl and aryl;
wherein R3 is selected from the group consisting essentially of hydrogen, alkyl and aryl.
7. A method of preparing a threo-isomer of a derivative of sphingosine, wherein said derivative of sphingosine comprises the formula: ##STR15## wherein X and Y are selected from the group consisting essentially of hydrogen, hydroxyl, alkoxy, amino, alkylamino and dialkylamino and wherein R1 is selected from the group consisting essentially of hydrogen, alkyl and aryl, comprising:
a) reducing serine methyl ester by a hydride reagent to from an aldehyde or aldehyde derivative that is capable of forming said derivative of sphingosine in substantially the same manner as said aldehyde, said aldehyde having the formula: ##STR16## b) adding acetylide anions to said aldehyde or aldehyde derivative to form an erythro-isomer of propargyl alcohol;
c) inverting said propargyl alcohol by SN 2 inversion to form a threo-isomer of propargyl alcohol;
d) acidifying said threo-isomer to form a diol having the formula: ##STR17## wherein R is selected from the group consisting essentially of hydrogen, alkyl and aryl;
e) cleaving said diol to form an amine having the formula: ##STR18## f) reducing said amine to form an alkene having the formula: ##STR19## and g) adding a functional group selected from the group consisting of hydrogen, hydroxyl, alkoxy, amino, alkylamino, and dialkylamino to the 4 and 5 position of said alkene to form said threo-isomer of a derivative of sphingosine.
8. The method of claim 7, wherein said hydride reagent is an aluminum hydride reagent.
9. The method of claim 7, wherein said hydride reagent is lithium aluminum hydride.
10. The method of claim 7, wherein said reduction of serine methyl ester is accomplished by DIBAL reduction.
11. The method of claim 7, wherein said acetylide anions comprise alkali acetylides.
12. The method of claim 7, wherein said acetylide anions comprise 1-lithiopentadecyne.
13. The method of claim 7, wherein said SN 2 inversion is a Mitsunobu inversion.
14. The method of claim 7, wherein said substituted derivative of sphingosine has a 2-aminopropane 1, 3 diol head group.
15. The method of claim 7, further comprising the step of adding a functional group to said derivative of sphingosine to form a compound of the formula: ##STR20## wherein W is selected from the group consisting essentially of hydrogen, hydroxyl, alkoxy, amino, alkylamino and dialkyamino;
wherein X is selected from the group consisting essentially of hydrogen, hydroxyl, alkoxy, amino, alkylamino and dialkyamino;
wherein Y is selected from the group consisting essentially of hydrogen, hydroxyl, alkoxy, amino, alkylamino and dialkyamino;
wherein Z is selected from the group consisting essentially of hydrogen, hydroxyl, alkoxy, amino, alkylamino and dialkyamino;
wherein R1 is selected from the group consisting essentially of hydrogen, alkyl and aryl;
wherein R2 is selected from the group consisting essentially of hydrogen, alkyl and aryl;
wherein R3 is selected from the group consisting essentially of hydrogen, alkyl and aryl.
16. The method of claim 1, wherein said derivative of sphingosine comprises the formula: ##STR21## wherein W is hydroxyl; wherein X is hydrogen;
wherein Y is hydroxyl;
wherein Z is hydroxyl;
wherein R1 is alkyl;
wherein R2 is hydrogen, and
wherein R3 is hydrogen.
17. A method of preparing an erythro isomer of a derivative of sphingosine, wherein said derivative of sphingosine comprises the formula: ##STR22## wherein X and Y are selected from the group consisting essentially of hydrogen, hydroxyl, alkoxy, amino, alkylamino and dialkylamino and wherein R1 is selected from the group consisting essentially of hydrogen, alkyl and aryl, comprising the steps of:
a) adding acetylide anions to an aldehyde or a derivative of said aldehyde that is capable of forming said derivative of sphingosine in substantially the same manner as said aldehyde to form an erythro-isomer of propargyl alcohol, said aldehyde having the formula: ##STR23## b) acidifying said propargyl alcohol to form a diol having the formula: ##STR24## wherein R is selected from the group consisting essentially of hydrogen, alkyl and aryl;
c) cleaving said diol to form an amine having the formula: ##STR25## d) reducing said amine to form an alkene having the formula: ##STR26## and e) adding a functional group selected from the group consisting of hydrogen, hydroxyl, alkoxy, amino, alkylamino, and dialkylamino to the 4 and 5 position of said alkene to form said erythro-isomer of a derivative of sphingosine.
18. The method of claim 17, wherein said acetylide anions comprise alkali acetylides.
19. The method of claim 17, wherein said acetylide anions comprise 1-lighiopentadecyne.
20. The method of claim 17, wherein said substituted derivative of sphingosine has a 2-aminopropane 1,3-diol head group.
21. The method of claim 17, further comprising the step of adding a functional group to said derivative of sphingosine to form a compound of the formula: ##STR27## wherein W is selected from the group consisting essentially of hydrogen, hydroxyl, alkoxy, amino, alkylamino and dialkyamino;
wherein X is selected from the group consisting essentially of hydrogen, hydroxyl, alkoxy, amino, alkylamino and dialkyamino;
wherein Y is selected from the group consisting essentially of hydrogen, hydroxyl, alkoxy, amino, alkylamino and dialkyamino;
wherein Z is selected from the group consisting essentially of hydrogen, hydroxyl, alkoxy, amino, alkylamino and dialkyamino;
wherein R1 is selected from the group consisting essentially of hydrogen, alkyl and aryl;
wherein R2 is selected from the group consisting essentially of hydrogen, alkyl and aryl;
wherein R3 is selected from the group consisting essentially of hydrogen, alkyl and aryl.
22. A method of preparing an erythro isomer of a derivative of sphingosine, wherein said derivative of sphingosine comprises the formula: ##STR28## wherein X and Y are selected from the group consisting essentially of hydrogen, hydroxyl, alkoxy, amino, alkylamino and dialkylamino and wherein R1 is selected from the group consisting essentially of hydrogen, alkyl and aryl, comprising:
a) reducing serine methyl ester by a hydride reagent to form an aldehyde or aldehyde derivitive that is capable of forming said derivative of sphingosine in substantially the same manner as said aldehyde, said aldehyde having the formula: ##STR29## b) adding acetylide anions to an aldehyde or aldehyde derivative to form an erythro-isomer of propargyl alcohol;
c) acidifying said erythro-isomer to form a diol having the formula: ##STR30## wherein R is selected from the group consisting essentially of hydrogen, alkyl and aryl;
d) cleaving said diol to form an amine having the formula: ##STR31## e) reducing said amine to form an alkene having the formula: ##STR32## and f) adding a functional group selected from the group consisting of hydrogen, hydroxyl, alkoxy, amino, alkylamino, and dialkylamino to the 4 and 5 position of said alkene to form said erythro-isomer of a derivative of sphingosine.
23. The method of claim 22, wherein said hydride reagent is an aluminum hydride reagent.
24. The method of claim 22, wherein said hydride reagent is lithium aluminum hydride.
25. The method of claim 22, wherein said reduction of serine methyl ester is accomplished by DIBAL reduction.
26. The method of claim 22, wherein said acetylide anions comprise alkali acetylides.
27. The method of claim 22, wherein said acetylide anions comprise 1-lithiopentadecyne.
28. The method of claim 22, wherein said substituted derivative of sphingosine has a 2-aminopropane-1,3-diol head group.
29. The method of claim 22, further comprising the step of adding a functional group to said derivative of sphingosine to form a compound of the formula: ##STR33## wherein W is selected from the group consisting essentially of hydrogen, hydroxyl, alkoxy, amino, alkylamino and dialkyamino;
wherein X is selected from the group consisting essentially of hydrogen, hydroxyl, alkoxy, amino, alkylamino and dialkyamino;
wherein Y is selected from the group consisting essentially of hydrogen, hydroxyl, alkoxy, amino, alkylamino and dialkamino;
wherein Z is selected from the group consisting essentially of hydrogen, hydroxyl, alkoxy, amino, alkylamino and dialkyamino;
wherein R1 is selected from the group consisting essentially of hydrogen, alkyl and aryl;
wherein R2 is selected from the group consisting essentially of hydrogen, alkyl and aryl;
wherein R3 is selected from the group consisting essentially of hydrogen, alkyl and aryl.
30. A method of preparing a threo-isomer of sphingosine or a derivative thereof, wherein said derivative of sphingosine comprises the formula: ##STR34## wherein R1 is selected from the group consisting essentially of hydrogen, alkyl and aryl, comprising the steps of:
a) adding acetylide anions to an aldehyde or a derivative of said aldehyde that is capable of forming said sphingosine or derivative thereof in substantially the same manner as said aldehyde to form an erythro-isomer of propargyl alcohol, said aldehyde having the formula: ##STR35## b) inverting said propargyl alcohol by SN 2 inversion to form a threo-isomer of propargyl alcohol;
c) acidifying said threo-isomer to form a diol having the formula: ##STR36## wherein R is selected from the group consisting essentially of hydrogen, alkyl and aryl;
d) cleaving said diol to form an amine having the formula: ##STR37## and e) reducing said amine to form an alkene having the formula: ##STR38##
31. The method of claim 30, wherein said acetylide anions comprise alkali acetylides.
32. The method of claim 30, wherein said acetylide anions comprise 1-lithiopentadecyne.
33. The method of claim 30, wherein said SN 2 inversion is a Mitsunobu inversion.
34. The method of claim 30, wherein said derivative of sphingosine has a 2-aminopropane 1,3-diol head group.
35. The method of claim 30, further comprising the step of adding a functional group to said derivative of sphingosine to form a compound of the formula: ##STR39## wherein W is selected from the group consisting essentially of hydrogen, hydroxyl, alkoxy, amino, alkylamino and dialkyamino;
wherein Z is selected from the group consisting essentially of hydrogen, hydroxyl, alkoxy, amino, alkylamino and dialkyamino;
wherein R1 is selected from the group consisting essentially of hydrogen, alkyl and aryl;
wherein R3 is selected from the group consisting essentially of hydrogen, alkyl and aryl;
wherein R3 is selected from the group consisting essentially of hydrogen, alkyl and aryl.
36. A method of preparing an erythro-isomer of sphingosine or a derivative thereof, wherein said derivative of sphingosine comprises the formula: ##STR40## wherein R1 is selected from the group consisting essentially of hydrogen, alkyl and aryl, comprising the steps of:
a) adding acetylide anions to an aldehyde or a derivative of said aldehyde that is capable of forming said sphingosine or derivative thereof in substantially the same manner as said aldehyde to form an erythro-isomer of propargyl alcohol, said aldehyde having the formula: ##STR41## b) acidifying said propargyl alcohol to form a diol having the formula: ##STR42## wherein R is selected from the group consisting essentially of hydrogen, alkyl and aryl;
c) cleaving said diol to form an amine having the formula: ##STR43## and d) reducing said amine to form an alkene having the formula: ##STR44##
37. The method of claim 36, wherein said acetylide anions comprise alkali acetylides.
38. The method of claim 36, wherein said acetylide anions comprise 1-lithiopentadecyne.
39. The method of claim 36, wherein said derivative of sphingosine has a 2-aminopropane 1,3-diol head group.
40. The method of claim 36, further comprising the step of adding a functional group to said derivative of sphingosine to form a compound of the formula: ##STR45## wherein W is selected from the group consisting essentially of hydrogen, hydroxyl, alkoxy, amino, alkylamino and dialkyamino;
wherein Z is selected from the group consisting essentially of hydrogen, hydroxyl, alkoxy, amino, alkylamino and dialkyamino;
wherein R1 is selected from the group consisting essentially of hydrogen, alkyl and aryl;
wherein R2 is selected from the group consisting essentially of hydrogen, alkyl and aryl;
wherein R3 is selected from the group consisting essentially of hydrogen, alkyl and aryl.
41. The method of claim 1, wherein approximately equal molar ratios of said acetylide anions and said aldehyde react.
42. The method of claim 7, wherein approximately equal molar ratios of said acetylide anions and said aldehyde react.
43. The method of claim 17, wherein approximately equal molar ratios of said acetylide anions and said aldehyde react.
44. The method of claim 22, wherein approximately equal molar ratios of said acetylide anions and said aldehyde react.
45. The method of claim 30, wherein approximately equal molar ratios of said acetylide anions and said aldehyde react.
46. The method of claim 36, wherein approximately equal molar ratios of said acetylide anions and said aldehyde react.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/208,390 US5110987A (en) | 1988-06-17 | 1988-06-17 | Method of preparing sphingosine derivatives |
| PCT/US1989/002633 WO1989012632A1 (en) | 1988-06-17 | 1989-06-14 | Method of preparing sphingosine derivatives and an aldehyde used therein |
| AU38634/89A AU3863489A (en) | 1988-06-17 | 1989-06-14 | Method of preparing sphingosine derivatives and an aldehyde used therein |
| CA000603121A CA1340549C (en) | 1988-06-17 | 1989-06-16 | Method of preparing sphingosine derivatives |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/208,390 US5110987A (en) | 1988-06-17 | 1988-06-17 | Method of preparing sphingosine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US5110987A true US5110987A (en) | 1992-05-05 |
Family
ID=22774438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US07/208,390 Expired - Lifetime US5110987A (en) | 1988-06-17 | 1988-06-17 | Method of preparing sphingosine derivatives |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US5110987A (en) |
| AU (1) | AU3863489A (en) |
| CA (1) | CA1340549C (en) |
| WO (1) | WO1989012632A1 (en) |
Cited By (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5391800A (en) * | 1992-04-03 | 1995-02-21 | The Biomembrane Institute | Method for inhibition of cell motility by sphingosine-1-phosphate, its derivatives and mimetics and method of synthesizing sphingosine-1-phosphate and its derivatives |
| US5488166A (en) * | 1993-10-18 | 1996-01-30 | Virginia Tech Intellectual Properties, Inc. | Synthesis of sphingosines |
| US5616332A (en) * | 1993-07-23 | 1997-04-01 | Herstein; Morris | Cosmetic skin-renewal-stimulating composition with long-term irritation control |
| US5618523A (en) * | 1991-02-21 | 1997-04-08 | L'oreal | Ceramides, process for their preparation and their applications in the cosmetic and dermopharmaceutical fields |
| US6127578A (en) * | 1991-08-05 | 2000-10-03 | Emory University | Method of altering sphingolipid metabolism and detecting fumonisin ingestion and contamination |
| US6194391B1 (en) | 1998-06-24 | 2001-02-27 | Emory University | 3′-azido-2′,3′-dideoxyuridine administration to treat HIV and related test protocol |
| US6469148B1 (en) | 1999-05-10 | 2002-10-22 | Lipiderm Ltd. | Process for large scale preparation of sphingosines and ceramides |
| US6610835B1 (en) | 1998-02-12 | 2003-08-26 | Emory University | Sphingolipid derivatives and their methods of use |
| US6720184B1 (en) | 1991-08-05 | 2004-04-13 | Emory University | Method of altering sphingolipid metabolism and detecting fumonisin ingestion and contamination |
| US20070232682A1 (en) * | 2006-03-28 | 2007-10-04 | Allergan, Inc. | Indole Compounds having sphingosine-1-phosphate (S1P) receptor antagonist |
| US20070281320A1 (en) * | 2006-05-31 | 2007-12-06 | Sabbadini Roger A | Novel Bioactive Lipid Derivatives, and Methods of Making and Using Same |
| US20080090303A1 (en) * | 2006-05-31 | 2008-04-17 | Sabbadini Roger A | Methods and Reagents for Detecting Bioactive Lipids |
| US20080145360A1 (en) * | 2006-05-31 | 2008-06-19 | Sabbadini Roger A | Immune-Derived Moieties Reactive Against Lysophosphatidic Acid |
| US20080171772A1 (en) * | 2007-01-11 | 2008-07-17 | Beard Richard L | 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity |
| WO2008089015A1 (en) | 2007-01-11 | 2008-07-24 | Allergan, Inc. | 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity |
| US20090294364A1 (en) * | 2004-05-21 | 2009-12-03 | Bayer Technology Services Gmbh | Method for the production of chemical and pharmaceutical products with integrated multicolumn chromatography |
| US20100041715A1 (en) * | 2008-08-12 | 2010-02-18 | Allergan, Inc. | Sphingosine-1-phosphate (s1p) receptor antagonists and methods for use thereof |
| US7737173B2 (en) | 2006-02-15 | 2010-06-15 | Allergan, Inc. | Indole-3-carboxylic acid amide, ester, thioamide and thiol ester compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (S1P) receptor antagonist biological activity |
| US20100240614A1 (en) * | 2007-09-24 | 2010-09-23 | Beard Richard L | Indole Compounds Bearing Aryl or Heteroaryl Groups Having Sphingosine 1-Phosphate (S1P) Receptor Biological Activity |
| WO2011008475A1 (en) | 2009-06-30 | 2011-01-20 | Allergan, Inc. | Optionally substituted 2-(arylmethyl, aryloxy or arylthio) -n- pyridin-2 -yl-aryl acetamide or 2, 2-bis (aryl) -n-pyridin-2-yl acetamide compounds as medicaments for the treatment of eye diseases |
| WO2011019681A1 (en) | 2009-08-11 | 2011-02-17 | Allergan, Inc. | Selective sphingosine-1-phosphate receptor antagonists |
| WO2011028927A1 (en) | 2009-09-04 | 2011-03-10 | Allergan, Inc. | Selective sphingosine-1-phosphate receptor antagonists |
| WO2011041287A1 (en) | 2009-09-29 | 2011-04-07 | Allergan, Inc. | Condensed ring pyridine compounds as subtype-selective modulators of sphingosine-1-phosphate-2 (s1p2) receptors |
| US20110152241A1 (en) * | 2009-11-24 | 2011-06-23 | Allergan, Inc. | Novel compounds as receptor modulators with therapeutic utility |
| US8143291B2 (en) | 2008-05-09 | 2012-03-27 | Allergan, Inc. | Indole compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (S1P) receptor biological activity |
| US8653270B2 (en) | 2010-11-22 | 2014-02-18 | Allergan, Inc. | Compounds as receptor modulators with therapeutic utility |
| US8741875B2 (en) | 2009-11-24 | 2014-06-03 | Allergan, Inc. | Compounds as receptor modulators with therapeutic utility |
| US9274130B2 (en) | 2006-05-31 | 2016-03-01 | Lpath, Inc. | Prevention and treatment of pain using antibodies to lysophosphatidic acid |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022158993A1 (en) | 2021-01-25 | 2022-07-28 | Carbocode S.A. | Method for the production of d-erythro-sphingosine and analogs thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2194294A (en) * | 1938-07-16 | 1940-03-19 | Du Pont | Preparation of n-substituted alkylol amines |
| GB1444552A (en) * | 1972-12-05 | 1976-08-04 | Beecham Group Ltd | Aminoethanols |
| US4463192A (en) * | 1983-07-05 | 1984-07-31 | Texaco Inc. | Process for the reduction of an N-hydrocarbyl substituted oxazolidine with carbon monoxide to form the corresponding N-hydrocarbyl substituted alkanolamine |
-
1988
- 1988-06-17 US US07/208,390 patent/US5110987A/en not_active Expired - Lifetime
-
1989
- 1989-06-14 AU AU38634/89A patent/AU3863489A/en not_active Abandoned
- 1989-06-14 WO PCT/US1989/002633 patent/WO1989012632A1/en unknown
- 1989-06-16 CA CA000603121A patent/CA1340549C/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2194294A (en) * | 1938-07-16 | 1940-03-19 | Du Pont | Preparation of n-substituted alkylol amines |
| GB1444552A (en) * | 1972-12-05 | 1976-08-04 | Beecham Group Ltd | Aminoethanols |
| US4463192A (en) * | 1983-07-05 | 1984-07-31 | Texaco Inc. | Process for the reduction of an N-hydrocarbyl substituted oxazolidine with carbon monoxide to form the corresponding N-hydrocarbyl substituted alkanolamine |
Non-Patent Citations (6)
| Title |
|---|
| CA) 109:110149g of Garner et al. J. Org. Chem 1988, 53(18) 4395 8. * |
| CA) 109:110149g of Garner et al. J. Org. Chem 1988, 53(18) 4395-8. |
| CA) 109:230620a of Herold Helv. Chim. Acta 1988, 71(2) 354 62. * |
| CA) 109:230620a of Herold Helv. Chim. Acta 1988, 71(2) 354-62. |
| CA) 110:7935g of Radunz et al. Liebigs Ann. Chem 1988, (11), 1103 5. * |
| CA) 110:7935g of Radunz et al. Liebigs Ann. Chem 1988, (11), 1103-5. |
Cited By (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5618523A (en) * | 1991-02-21 | 1997-04-08 | L'oreal | Ceramides, process for their preparation and their applications in the cosmetic and dermopharmaceutical fields |
| US5773611A (en) * | 1991-02-21 | 1998-06-30 | L'oreal | Ceramides, process for their preparation and their applications in the cosmetic and dermopharmaceutical fields |
| US6720184B1 (en) | 1991-08-05 | 2004-04-13 | Emory University | Method of altering sphingolipid metabolism and detecting fumonisin ingestion and contamination |
| US6127578A (en) * | 1991-08-05 | 2000-10-03 | Emory University | Method of altering sphingolipid metabolism and detecting fumonisin ingestion and contamination |
| US5877167A (en) * | 1992-04-03 | 1999-03-02 | Otsuka America Pharmaceutical, Inc. | Method for inhibition of cell motility by sphingosine-1-phosphate and its derivatives |
| US5391800A (en) * | 1992-04-03 | 1995-02-21 | The Biomembrane Institute | Method for inhibition of cell motility by sphingosine-1-phosphate, its derivatives and mimetics and method of synthesizing sphingosine-1-phosphate and its derivatives |
| US5663404A (en) * | 1992-04-03 | 1997-09-02 | Oncomembrane | Sphingosine-1-phosphate essentially free of L-threo isomer |
| US5616332A (en) * | 1993-07-23 | 1997-04-01 | Herstein; Morris | Cosmetic skin-renewal-stimulating composition with long-term irritation control |
| US5488167A (en) * | 1993-10-18 | 1996-01-30 | Virginia Tech Intellectual Properties, Inc. | Synthesis of sphingosines |
| US5488166A (en) * | 1993-10-18 | 1996-01-30 | Virginia Tech Intellectual Properties, Inc. | Synthesis of sphingosines |
| US6610835B1 (en) | 1998-02-12 | 2003-08-26 | Emory University | Sphingolipid derivatives and their methods of use |
| US20040039212A1 (en) * | 1998-02-12 | 2004-02-26 | Liotta Dennis C. | Sphingolipid derivatives and their methods of use |
| US6194391B1 (en) | 1998-06-24 | 2001-02-27 | Emory University | 3′-azido-2′,3′-dideoxyuridine administration to treat HIV and related test protocol |
| US6602664B2 (en) | 1998-06-24 | 2003-08-05 | Emory University | 3′-azido-2′,3′-dideoxyuridine in an anti-HIV effectiveness test protocol |
| US6469148B1 (en) | 1999-05-10 | 2002-10-22 | Lipiderm Ltd. | Process for large scale preparation of sphingosines and ceramides |
| US20090294364A1 (en) * | 2004-05-21 | 2009-12-03 | Bayer Technology Services Gmbh | Method for the production of chemical and pharmaceutical products with integrated multicolumn chromatography |
| US7737173B2 (en) | 2006-02-15 | 2010-06-15 | Allergan, Inc. | Indole-3-carboxylic acid amide, ester, thioamide and thiol ester compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (S1P) receptor antagonist biological activity |
| US20070232682A1 (en) * | 2006-03-28 | 2007-10-04 | Allergan, Inc. | Indole Compounds having sphingosine-1-phosphate (S1P) receptor antagonist |
| US8097644B2 (en) | 2006-03-28 | 2012-01-17 | Allergan, Inc. | Indole compounds having sphingosine-1-phosphate (S1P) receptor antagonist |
| US20080090303A1 (en) * | 2006-05-31 | 2008-04-17 | Sabbadini Roger A | Methods and Reagents for Detecting Bioactive Lipids |
| US20080145360A1 (en) * | 2006-05-31 | 2008-06-19 | Sabbadini Roger A | Immune-Derived Moieties Reactive Against Lysophosphatidic Acid |
| US20070281320A1 (en) * | 2006-05-31 | 2007-12-06 | Sabbadini Roger A | Novel Bioactive Lipid Derivatives, and Methods of Making and Using Same |
| US9274130B2 (en) | 2006-05-31 | 2016-03-01 | Lpath, Inc. | Prevention and treatment of pain using antibodies to lysophosphatidic acid |
| US9274129B2 (en) | 2006-05-31 | 2016-03-01 | Lpath, Inc. | Methods and reagents for detecting bioactive lipids |
| US9217749B2 (en) | 2006-05-31 | 2015-12-22 | Lpath, Inc. | Immune-derived moieties reactive against lysophosphatidic acid |
| US8796429B2 (en) * | 2006-05-31 | 2014-08-05 | Lpath, Inc. | Bioactive lipid derivatives, and methods of making and using same |
| US20080171772A1 (en) * | 2007-01-11 | 2008-07-17 | Beard Richard L | 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity |
| WO2008089015A1 (en) | 2007-01-11 | 2008-07-24 | Allergan, Inc. | 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity |
| US8524917B2 (en) | 2007-01-11 | 2013-09-03 | Allergan, Inc. | 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity |
| US20100240614A1 (en) * | 2007-09-24 | 2010-09-23 | Beard Richard L | Indole Compounds Bearing Aryl or Heteroaryl Groups Having Sphingosine 1-Phosphate (S1P) Receptor Biological Activity |
| US7888336B2 (en) | 2007-09-24 | 2011-02-15 | Allergan, Inc. | Indole compounds bearing aryl or heteroaryl groups having sphingosine 1-phosphate (S1P) receptor biological activity |
| US8143291B2 (en) | 2008-05-09 | 2012-03-27 | Allergan, Inc. | Indole compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (S1P) receptor biological activity |
| US20100041715A1 (en) * | 2008-08-12 | 2010-02-18 | Allergan, Inc. | Sphingosine-1-phosphate (s1p) receptor antagonists and methods for use thereof |
| US8049037B2 (en) | 2008-08-12 | 2011-11-01 | Allergan, Inc. | Sphingosine-1-phosphate (S1P) receptor antagonists and methods for use thereof |
| WO2011008475A1 (en) | 2009-06-30 | 2011-01-20 | Allergan, Inc. | Optionally substituted 2-(arylmethyl, aryloxy or arylthio) -n- pyridin-2 -yl-aryl acetamide or 2, 2-bis (aryl) -n-pyridin-2-yl acetamide compounds as medicaments for the treatment of eye diseases |
| US8168795B2 (en) | 2009-08-11 | 2012-05-01 | Allergan, Inc. | Selective sphingosine-1-phosphate receptor antagonists |
| US20110039866A1 (en) * | 2009-08-11 | 2011-02-17 | Allergan, Inc. | Selective sphingosine-1-phosphate receptor antagonists |
| WO2011019681A1 (en) | 2009-08-11 | 2011-02-17 | Allergan, Inc. | Selective sphingosine-1-phosphate receptor antagonists |
| WO2011028927A1 (en) | 2009-09-04 | 2011-03-10 | Allergan, Inc. | Selective sphingosine-1-phosphate receptor antagonists |
| US8703797B2 (en) | 2009-09-29 | 2014-04-22 | Allergan, Inc. | Condensed ring pyridine compounds as subtype-selective modulators of sphingosine-1-phosphate-2 (S1P2) receptors |
| US8507682B2 (en) | 2009-09-29 | 2013-08-13 | Allergan, Inc. | Condensed ring pyridine compounds as subtype-selective modulators of sphingosine-1-phosphate-2 (S1P2) receptors |
| WO2011041287A1 (en) | 2009-09-29 | 2011-04-07 | Allergan, Inc. | Condensed ring pyridine compounds as subtype-selective modulators of sphingosine-1-phosphate-2 (s1p2) receptors |
| US8741875B2 (en) | 2009-11-24 | 2014-06-03 | Allergan, Inc. | Compounds as receptor modulators with therapeutic utility |
| US8703745B1 (en) | 2009-11-24 | 2014-04-22 | Allergan, Inc. | Compounds as receptor modulators with therapeutic utility |
| US8653062B2 (en) | 2009-11-24 | 2014-02-18 | Allergan, Inc. | Compounds as receptor modulators with therapeutic utility |
| US8828973B2 (en) | 2009-11-24 | 2014-09-09 | Allergan, Inc. | Compounds as receptor modulators with therapeutic utility |
| US8440644B2 (en) | 2009-11-24 | 2013-05-14 | Allergan, Inc. | Compounds as receptor modulators with therapeutic utility |
| US20110212925A1 (en) * | 2009-11-24 | 2011-09-01 | Allergan, Inc. | Novel compounds as receptor modulators with therapeutic utility |
| US20110152241A1 (en) * | 2009-11-24 | 2011-06-23 | Allergan, Inc. | Novel compounds as receptor modulators with therapeutic utility |
| US8703746B2 (en) | 2010-11-22 | 2014-04-22 | Allergan, Inc. | Compounds as receptor modulators with therapeutic utility |
| US8653270B2 (en) | 2010-11-22 | 2014-02-18 | Allergan, Inc. | Compounds as receptor modulators with therapeutic utility |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1989012632A1 (en) | 1989-12-28 |
| AU3863489A (en) | 1990-01-12 |
| CA1340549C (en) | 1999-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5110987A (en) | Method of preparing sphingosine derivatives | |
| KR960000758B1 (en) | Optically active hydroxybenzylamine derivative, optically active | |
| CN114315609B (en) | Technological method for preparing cis-2-aminocyclohexanol | |
| EP1951726A2 (en) | Method for the preparation of escitalopram | |
| CN112479967B (en) | Biliverdin compound, and preparation method and application thereof | |
| JPH0386873A (en) | Manufacture of 1, 3-dioxoran- ketone | |
| GB2036744A (en) | Eburnane derivatives | |
| US6350902B2 (en) | Process for the selective N-formylation of N-hydroxylamines | |
| US6639095B1 (en) | Process for preparing optically active α-hydroxy acids and derivatives thereof | |
| JPS62155268A (en) | Synthesis of nizatidine | |
| JP3770678B2 (en) | Optically active alcohol and its carboxylic acid ester | |
| US20010031896A1 (en) | Process for the selective N-formylation of N-hydroxylamines | |
| JPH0142253B2 (en) | ||
| DE19814801A1 (en) | Process for the preparation of 1,3,4-trisubstituted 1,2,4-triazolium salts | |
| JP3272340B2 (en) | Method for producing 1-[(cyclopent-3-en-1-yl) methyl] -5-ethyl-6- (3,5-dimethylbenzoyl) -2,4-pyrimidinedione | |
| JP2974181B2 (en) | A new method for producing cyclobutanol | |
| JPS6254416B2 (en) | ||
| US5132457A (en) | Stereospecific synthesis of 2(R)-2-methyl-3-dimethylamino-propiophenone (d-DAMP) | |
| EP2938595B1 (en) | Method for the synthesis of a hydrazine that can be used in the treatment of the papilloma virus | |
| KR20050062944A (en) | New process for preparing diisopropyl ((1-((2-amino-6-chloro-9h-purin-9-yl)methyl)cyclopropyl)oxy)-methylphosphonate | |
| JPH0623180B2 (en) | Cyanoguanidine derivative and method for producing the same | |
| JP2973546B2 (en) | Optically active 4-benzoyloxymethyl-2-oxazolidinone and method for producing the same | |
| JP2833672B2 (en) | Method for producing β-ketonitrile | |
| JPS647973B2 (en) | ||
| JPH0597735A (en) | Production of optically active secondary alcohol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: EMORY UNIVERSITY, EMORY UNIVERSITY, ATLANTA, GEORG Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:LIOTTA, DENNIS;MERRILL, ALFRED H.;REEL/FRAME:004950/0880 Effective date: 19880713 Owner name: EMORY UNIVERSITY, EMORY UNIVERSITY, ATLANTA, GEORG Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LIOTTA, DENNIS;MERRILL, ALFRED H.;REEL/FRAME:004950/0880 Effective date: 19880713 |
|
| STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
| CC | Certificate of correction | ||
| FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
| FPAY | Fee payment |
Year of fee payment: 4 |
|
| FEPP | Fee payment procedure |
Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
| FPAY | Fee payment |
Year of fee payment: 8 |
|
| FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
| FPAY | Fee payment |
Year of fee payment: 12 |